Diamyd assigns Biovitrum development of production process for its diabetes drug GAD65

06-Apr-2005

Diamyd Medical AB and Biovitrum AB have signed an agreement covering the market adaptation of the production process for GAD65, Diamyd's product for the treatment of diabetes. The agreement means that Biovitrum is assigned the task of adapting the purification processes required for Phase III clinical trials and commercial production. Diamyd's diabetes drug is currently being tested in three different clinical trials (Phase II). The project will commence in April and will have a duration of six months.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances